This week the Chinese vaccine maker Sinovac announced it will launch a Phase I and II cllinical trial later this month to test its vaccine in over 552 children ages 3 to 17 in China. The trial will test both the safety of the vaccine and also examine whether it produces an immune response among the participants.
Experts say the need to conduct COVID-19 vaccine safety trials specifically among children is clear, but that holding the trials before a vaccine has been proved safe and effective among adults represents uncharted and ethically fraught territory.
The trial has already approved by the Chinese regulator, a Sinovac spokesperson said, according to Reuters. The Chinese vaccine maker’s shot is already in the final stage of study with adults.
CoronaVac, being tested in final-stage large-scale trials in Brazil, Indonesia and Turkey, has already been given to about 90% of the company’s employees and their families.
Sinovac said earlier this month CoronaVac appeared to be safe and able to induce antibodies for older people, while the vaccine-generated antibody levels were slightly lower than seen in younger adults, citing preliminary results from an early to mid stage trial .
CanSino Biologics and China National Biotec Group have also kicked off
testing in countries including Brazil, Russia, Indonesia, the United
Arab Emirates, Peru, Chile and Morocco.
No comments:
Post a Comment